1-10 of 10
Nicola J. Curtin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

Karen E. Parrish, Ling Cen, James Murray, David Calligaris, Sani Kizilbash, Rajendar K. Mittapalli, Brett L. Carlson, Mark A. Schroeder, Julieann Sludden, Alan V. Boddy, Nathalie Y.R. Agar, Nicola J. Curtin, William F. Elmquist, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12): 2735–2743.
DOI: https://doi.org/10.1158/1535-7163.MCT-15-0553
Published: 06 December 2015
View article
PDF
Includes: Supplementary data
Journal Articles

Abstract A220: Inhibition of PBMC PARP activity with the novel PARP 1/2 inhibitor BMN 673 in patients with advanced solid tumors.

Joshua W. Henshaw, Huiyu Zhou, Ashleigh Herriott, Miranda Patterson, Evelyn W. Wang, Don Musson, Johann de Bono, Lida A. Mina, Ramesh K. Ramanathan, Charles O'Neill, Andrew Dorr, Nicola J. Curtin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A220.
DOI: https://doi.org/10.1158/1535-7163.TARG-13-A220
Published: 01 November 2013
View article
Journal Articles

Abstract C75: Rucaparib (CO-338) accumulation and persistence of PARP inhibition in vitro and in vivo and efficacy of intermittent vs continuous schedules.

James C. Murray, Huw D. Thomas, Philip Berry, Suzanne Kyle, Christopher Jones, Ruth Plummer, Alan V. Boddy, Nicola J. Curtin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C75.
DOI: https://doi.org/10.1158/1535-7163.TARG-13-C75
Published: 01 November 2013
View article
Journal Articles

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

Michael A. Batey, Yan Zhao, Suzanne Kyle, Caroline Richardson, Andrew Slade, Niall M.B. Martin, Alan Lau, David R. Newell, Nicola J. Curtin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (6): 959–967.
DOI: https://doi.org/10.1158/1535-7163.MCT-12-0707
Published: 09 June 2013
View article
PDF
Journal Articles

Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

Joanne M. Munck, Michael A. Batey, Yan Zhao, Helen Jenkins, Caroline J. Richardson, Celine Cano, Michele Tavecchio, Jody Barbeau, Julia Bardos, Liam Cornell, Roger J. Griffin, Keith Menear, Andrew Slade, Pia Thommes, Niall M.B. Martin, David R. Newell, Graeme C.M. Smith, Nicola J. Curtin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (8): 1789–1798.
DOI: https://doi.org/10.1158/1535-7163.MCT-11-0535
Published: 08 August 2012
View article
PDF
Includes: Supplementary data
Journal Articles

The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice

Majid Ali, Marzieh Kamjoo, Huw D. Thomas, Suzanne Kyle, Ivanda Pavlovska, Muhammed Babur, Brian A. Telfer, Nicola J. Curtin, Kaye J. Williams
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (12): 2320–2329.
DOI: https://doi.org/10.1158/1535-7163.MCT-11-0356
Published: 07 December 2011
View article
PDF
Includes: Supplementary data
Journal Articles

Abstract A77: Efficacy of PARP inhibitor AG014699 in orthotopic GBM xenografts is limited by ineffective drug penetration into the central nervous system.

Ling Cen, Brett L. Carlson, Mark A. Schroeder, James Murray, Julieann Sludden, Alan V. Boddy, Nicola J. Curtin, Jann Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A77.
DOI: https://doi.org/10.1158/1535-7163.TARG-11-A77
Published: 12 November 2011
View article
Journal Articles

Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity

Huw D. Thomas, Kappusamy Saravanan, Lan-Zhen Wang, Mei-Ju Lin, Julian S. Northen, Hannah Barlow, Marion Barton, David R. Newell, Roger J. Griffin, Bernard T. Golding, Nicola J. Curtin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (7): 1828–1837.
DOI: https://doi.org/10.1158/1535-7163.MCT-08-1208
Published: 14 July 2009
View article
PDF
Includes: Supplementary data
Journal Articles

Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines

Michelle J. Clarke, Evan A. Mulligan, Patrick T. Grogan, Ann C. Mladek, Brett L. Carlson, Mark A. Schroeder, Nicola J. Curtin, Zhenkun Lou, Paul A. Decker, Wenting Wu, E. Ruth Plummer, Jann N. Sarkaria
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (2): 407–414.
DOI: https://doi.org/10.1158/1535-7163.MCT-08-0854
Published: 11 February 2009
View article
PDF
Journal Articles

Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

Huw D. Thomas, Christopher R. Calabrese, Michael A. Batey, Stacie Canan, Zdenek Hostomsky, Suzanne Kyle, Karen A. Maegley, David R. Newell, Donald Skalitzky, Lan-Zhen Wang, Stephen E. Webber, Nicola J. Curtin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (3): 945–956.
DOI: https://doi.org/10.1158/1535-7163.MCT-06-0552
Published: 15 March 2007
View article
PDF
Includes: Supplementary data